Parathyroid| Volume 161, ISSUE 1, P98-106, January 2017

Concentration of serum calcium is not correlated with symptoms or severity of primary hyperparathyroidism: An examination of 20,081 consecutive adults

Published:November 15, 2016DOI:


      Guidelines for operative treatment of primary hyperparathyroidism include calcium levels >1 mg/dL above normal. We sought to determine whether greater calcium concentrations were associated with increased symptoms or disease severity.


      A retrospective review of a prospectively maintained database of adults undergoing parathyroidectomy for primary hyperparathyroidism, grouped according to greatest preoperative calcium level: those patients with calcium concentrations between 10.0 and 11.0 mg/dL and those with >11.0 mg/dL. We compared subjective symptoms and objective measures of disease severity.


      The review included 20,081 adults who were split nearly evenly between calcium concentrations between 10.0 and 11.0 (10,430, 51.9%) and those with >11.0 mg/dL (9,651, 48.1%). In both groups, an absence of symptoms related to primary hyperparathyroidism was uncommon (<5%). All subjective and objective measures of disease severity were nearly identical with no significant differences (percentages for calcium concentrations between 10.0 and 11.0 and those with >11.0 mg/dL, respectively), including fatigue (72% for both groups), heartburn (37% vs 34%), bone pain (50% vs 48%), sleep disturbances (68% vs 65%), osteoporosis (40% in both groups), kidney stones (21% vs 22%), chronic kidney disease with glomerular filtration rate <60 (29% vs 32%), and hypertension (50% vs 53%).


      Serum calcium concentrations of greater than or less than 11 mg/dL are unrelated to symptoms and disease severity in primary hyperparathyroidism. There is no evidence to support a serum calcium threshold in parathyroidectomy guidelines.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Russell C.F.
        • Edis A.J.
        Surgery for primary hyperparathyroidism: experience with 500 consecutive cases and evaluation of the role of surgery in the asymptomatic patient.
        Br J Surg. 1982; 69: 244-247
        • Bilezikian J.P.
        • Brandi M.L.
        • Eastell R.
        • et al.
        Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop.
        J Clin Endocrinol Metab. 2014; 99: 3561-3569
      1. Diagnosis and management of asymptomatic primary hyperparathyroidism. NIH Consensus Statement. Oct 29–31, 1990.
        Consens Statement. 1990; 8: 1-18
        • Silverberg S.J.
        • Clarke B.L.
        • Peacock M.
        • et al.
        Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.
        J Clin Endocrinol Metab. 2014; 99: 3580-3594
        • Heath 3rd, H.
        • Hodgson S.F.
        • Kennedy M.A.
        Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community.
        N Eng J Med. 1980; 98: 1122-1129
        • Rubin M.R.
        • Bilezikian J.P.
        • McMahon D.J.
        • et al.
        The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years.
        J Clin Endocrinol Metab. 2008; 93: 3462-3470
        • Bilezikian J.P.
        • Potts Jr., J.T.
        • El-Hajj Fuleihan G.
        • Kleerekoper M.
        • Neer R.
        • Peacock M.
        • et al.
        Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century.
        J Clin Endocrinol Metab. 2002; 87: 5353-5361
        • Bilezikian J.P.
        • Khan A.A.
        • Potts J.T.
        Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Third International Workshop.
        J Clin Endocrinol Metab. 2009; 94: 335-339
        • Rao D.S.
        • Phillips E.R.
        • Divine G.W.
        • Talpos G.B.
        Randomized controlled trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism.
        J Clin Endocrinol Metab. 2004; 89: 5415-5422
        • Yu N.
        • Donnan P.T.
        • Flynn R.W.
        • et al.
        Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS).
        Clin Endocrinol (Oxf). 2010; 73: 30-34
        • Cannon J.
        • Lew J.I.
        • Solorzano C.C.
        Parathyroidectomy for hypercalcemic crisis: 40 years’ experience and long-term outcomes.
        Surgery. 2010; 148: 807-812
        • Silverberg S.J.
        • Shane E.
        • Jacobs T.P.
        • Siris E.
        • Bilezikian J.P.
        A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.
        N Engl J Med. 1999; 341: 1249-1255
        • Norman J.
        • Goodman A.
        • Politz D.
        Calcium, parathyroid hormone, and vitamin D in patients with primary hyperparathyroidism: normograms developed from 10,000 cases.
        Endocrine Practice. 2011; 17: 384-394
        • Van’t Leven M.
        • Zielhuis G.A.
        • van der Meer J.W.
        • Verbeek A.L.
        • Bleijenberg G.
        Fatigue and chronic fatigue syndrome-like complaints in the general population.
        Eur J Public Health. 2010; 20: 251-257
        • Roth T.
        Insomnia: definition, prevalence, etiology, and consequences.
        J Clin Sleep Med. 2007; 3: S7-S10
        • Blanchard C.
        • Mathonnet M.
        • Sebag F.
        • et al.
        Surgery for ‘asymptomatic’ mild primary hyperparathyroidism improves some clinical symptoms postoperatively.
        Eur J Endocrinol. 2013; 169: 665-672
        • Roman S.A.
        • Sosa J.A.
        • Pietrzak R.H.
        • et al.
        The effects of serum calcium and parathyroid hormone changes on psychological and cognitive function in patients undergoing parathyroidectomy for primary hyperparathyroidism.
        Ann Surg. 2011; 253: 131-137
        • Norman J.
        • Politz D.
        • Lopez J.
        • Boone D.
        • Stojadinovic A.
        Surgical cure of primary hyperparathyroidism ameliorates gastroesophageal reflux symptoms.
        World J Surg. 2015; 39: 706-712
        • Murray S.E.
        • Pathak P.R.
        • Schaefer S.C.
        • Chen H.
        • Sippel R.S.
        Improvement of sleep disturbance and insomnia following parathyroidectomy for primary hyperparathyroidism.
        World J Surg. 2014; 38: 542-548
        • Adkisson C.D.
        • Yip L.
        • Armstrong M.J.
        • Stang M.T.
        • Carty S.E.
        • McCoy K.L.
        Fibromyalgia symptoms and medication requirements respond to parathyroidectomy.
        Surgery. 2014; 156: 1614-1620
        • Coker L.H.
        • Rorie K.
        • Cantley L.
        • et al.
        Primary hyperparathyroidism, cognition, and health-related quality of life.
        Ann Surg. 2005; 242: 642-650
        • Sosa J.A.
        • Powe N.R.
        • Levine M.A.
        • Udelsman R.
        • Zeiger M.A.
        Profile of a clinical practice: thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism: a national survey of endocrine surgeons.
        J Clin Endocrinol Metab. 1998; 83: 2658-2665
        • Norman J.G.
        • Politz D.E.
        Safety of immediate discharge after parathyroidectomy: a prospective study of 3,000 consecutive patients.
        Endocr Pract. 2007; 13: 105-113